first_imgThursday 14 October 2010 9:07 pm Tags: NULL KCS-content whatsapp Read This NextRicky Schroder Calls Foo Fighters’ Dave Grohl ‘Ignorant Punk’ forThe WrapCNN’s Brian Stelter Draws Criticism for Asking Jen Psaki: ‘What Does theThe WrapDid Donald Trump Wear His Pants Backwards? Kriss Kross Memes Have AlreadyThe WrapHarvey Weinstein to Be Extradited to California to Face Sexual AssaultThe Wrap’Sex and the City’ Sequel Series at HBO Max Adds 4 More ReturningThe WrapPink Floyd’s Roger Waters Denies Zuckerberg’s Request to Use Song in Ad:The Wrap’The View’: Meghan McCain Calls VP Kamala Harris a ‘Moron’ for BorderThe WrapNewsmax Rejected Matt Gaetz When Congressman ‘Reached Out’ for a JobThe Wrap2 HFPA Members Resign Citing a Culture of ‘Corruption and Verbal Abuse’The Wrap Share SHARES in Actelion jumped again yesterday on new market talk the Swiss biotech group could be the next bid target in the pharmaceuticals sector.Traders said markets were speculating that GlaxoSmithKline, which has a drug partnership with Actelion, could offer 72 Swiss francs (£47.30) per share. Sanofi-Aventis launched a $18.5bn hostile bid for US biotech Genzyme last week, sparking chatter of more M&A in the sector. Actelion shares, which had lost nearly a quarter of their value this year, closed up 6.6 per cent at 53 francs, outperforming a 0.5 per cent weaker European healthcare sector index. The stock has gained over 30 per cent this month.Analysts have cited Amgen, Roche, BristolMyersSquibb, AstraZeneca, Bayer and Novartis as possible buyers. whatsapp Actelion shares jump as market looks for next takeover target Show Comments ▼last_img


Leave a Reply

Your email address will not be published. Name and email are required